Whole Agonist-Stimulated T cells

Whole Agonist-Stimulated T (WAST) cells are an autologous adoptive cell therapy developed by the Tianjin Medical University Cancer Institute and Hospital. This therapy involves the ex vivo expansion and activation of a patient's own T lymphocytes using a specific 'whole agonist' stimulation protocol designed to enhance their anti-tumor effector functions and proliferative capacity. WAST cells are primarily being investigated as a second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1 inhibitors. In clinical settings, these cells are typically administered via intravenous infusion, often in combination with chemotherapy agents like docetaxel, to revitalize the anti-tumor immune response and overcome the immunosuppressive environment of refractory tumors.

Other names

Whole Agonist-Stimulated T (WAST) cellsWhole Agonist-Stimulated T cells-Tianjin Medical University Cancer Institute and Hospital-non-small cell lung cancer